EUVIMEDEUVIMED entdecken
Crossref

Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions

I. Karam, B. Melosky

Current Oncology · 2012

DOI: 10.3747//co.19.949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2012. Verfasst von I. Karam und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Karam, I., & Melosky, B. (2012). Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. Current Oncology. https://doi.org/10.3747//co.19.949

Vancouver

Karam I, Melosky B. Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. Current Oncology. 2012. doi:10.3747//co.19.949

BibTeX
@article{Karam2012,
  author = {Karam, I. and Melosky, B.},
  title = {Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions},
  journal = {Current Oncology},
  year = {2012},
  doi = {10.3747//co.19.949}
}
Kostenlos starten →